Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 3, 2016, Pages 220-222

  Mansfield, A S ^a   Dong, H ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

ANTIBODY DETECTION; ARTICLE; CANCER IMMUNOTHERAPY; CELL HETEROGENEITY; HUMAN; IMMUNOASSAY; NON SMALL CELL LUNG CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; ADOPTIVE IMMUNOTHERAPY; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS;

ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; PATIENT SELECTION; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84988971695     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.360     Document Type: Article

References (6)

1. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
2. Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365–1369 (1999).
3. Frigola, X. et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res. 17, 1915–1923 (2011).
4. McLaughlin, J. et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 1–9 (2015).
5. Ilie, M. et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann. Oncol. 27, 147–153 (2016).
6. Mansfield, A.S. et al. Heterogeneity of programmed cell death-ligand 1 expression in multifocal lung cancer. Clin. Cancer Res. (2015); e-pub ahead of print.